Abstract Patients with insulin-dependent diabetes mellitus or noninsulin-dependent diabetes mellitus are frequently admitted to a hospital, usually for primary conditions other than diabetes. In addition to endorsing tight glycemic control in critical care units, current standards of care recommend treatment targets similar to those of outpatients for noncritically ill patients in hospital. Given the current prevalence of diabetes (DM), how best to address hyperglycemia in the Emergency Department (ED) is an increasingly relevant issue in which the principal goals are to minimize disruption of the metabolic state and achieve a stable glycemic balance as promptly as possible. Transition of care from the ED to an inpatient service can result in gaps in comprehensive care, particularly in patients with DM who may have other serious comorbidities. In critically ill patients, insulin therapy should be initiated for treatment of persistent hyperglycemia, starting at [180 mg/dL (10 mmol/ L). After insulin therapy has been started, the standard of care recommends a random glucose range of 140-180 mg/dL (7.8-10 mmol/L) for the majority of hospitalized patients. The traditional model of care among hospital-based physicians has been to treat the diabetic patient with a regular insulin on a sliding scale. Current evidence suggests that while this approach is straightforward, it may not be the best for patient care. Patients who present to the ED or are hospitalized often require an insulin regimen that can change rapidly as their condition changes. A basal/bolus insulin regimen fulfills those criteria and mimics a normal insulin profile.
Introduction
Patients with insulin-dependent diabetes mellitus (IDDM) or noninsulin-dependent diabetes mellitus (NIDDM) are frequently admitted to a hospital, usually for primary conditions other than diabetes. Diabetics are more likely to be hospitalized and have a longer length of hospital stay (LOS) compared with those without diabetes. Substantial observational evidence links hyperglycemia to poor outcomes in hospitalized patients. The American Diabetes Association (ADA) has therefore added recommendations for treatment of hyperglycemia in hospitalized patients to its annual Standards of Medical Care [1 • ].
In addition to endorsing tight glycemic control in critical care units, these standards of care recommend treatment targets similar to those of outpatients for noncritically ill patients in hospital. The latter recommendation is based on a lack of randomized controlled trial (RCT) evidence for treatment targets and glycemic goals in this population. The efforts of the ADA and the American Association of Clinical Endocrinologists (AACE) have contributed to a growing national movement in which the management of inpatient hyperglycemia is seen as a quality-of-care measure [1 • ].
Young Versus Old, Type 1 Versus Type 2
Diabetes mellitus (DM) remains more prevalent in older people compared with younger ones, as are other conditions such as hypertension, renal disease, and the need for joint replacement surgery. Thus, older individuals admitted to hospital are more likely to have diabetes mellitus (DM). Independent of age, glycemic control can become more challenging as a result of stress due to illness or a procedure in patients with or without a diagnose of DM. We can expect to see increasing rates of DM in patients in the Emergency Department (ED) and on inpatient services, due to the ongoing obesity epidemic and the aging population.
DM has traditionally been categorized as type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), in which type 1 refers to juvenile onset diabetes and type 2 to adult onset, Today, the lines between the two conditions have become blurred. Due to the obesity epidemic, more children, adolescents, and young adults develop type 2 diabetes than in the past. Adults with type 2 diabetes may use basal insulin in addition to oral medications or shorter-acting forms of insulin to achieve glycemic control. Unchanged, however, is the fact that patients with type 1 or juvenile onset diabetes do not produce insulin and those with type 2, formerly termed adult-onset DM are insensitive to it. These distinctions are important because insulin dosing approaches may differ markedly between patients with type 1 and type 2 diabetes who are in the throes of an acute illness.
Hyperglycemia in the ED
Given the current prevalence of DM, how best to address hyperglycemia in the ED is an increasingly relevant issue in which the principal goals are to minimize disruption of the metabolic state and achieve a stable glycemic balance as promptly as possible. However, although there is ample evidence in the literature to support attention to blood glucose control in patients who are critically ill or have had an acute MI, the paucity of controlled trials that explore the benefits and risks of ''loose'' or ''tight'' glycemic control in other hospitalized patients place emergency physicians and hospitalists in the challenging position of managing patients without a substantial body of evidence to guide them.
Hyperglycemia and Patient Outcomes
Despite the fact that hyperglycemia is associated with adverse patient outcomes, active intervention to normalize glycemia is associated with inconsistent results. Results of several trials have failed to show significant improvement in mortality with intensive glycemic control [2] , or have shown increased mortality risk [3] . Moreover, these and other trials have noted risk of severe hypoglycemia that can result from such efforts [2] [3] [4] [5] [6] [7] . These outcomes have contributed to confusion about specific glycemic targets and the means for achieving them in critically and noncritically ill patients.
A Call to Action
Transition of care from the ED to an inpatient service can result in gaps in comprehensive care, particularly in patients with DM who may have other serious comorbidities. Even in patients without a previous diagnosis of DM, uncontrolled hyperglycemia, regardless of cause during hospitalization, is associated with adverse outcomes and longer lengths of stay [8, 9] .
The remainder of this paper will focus on a hypothetical diabetic patient who presents to the ED with a non-ST-elevated myocardial infarction (NSTEMI), is found to be hyperglycemic, and will undergo interventional management during hospital admission. His clinical path will follow accepted protocols for NSTEMI, with focus on two continuing possible approaches to the hyperglycemia and management of diabetes: treatment with the traditional sliding scale insulin and treatment with basal insulin. See Table 1 for a case study of hospital-based management of DM.
Inpatient Diabetes Management
Management of diabetes in hospitalized patients may be directed by primary care physicians, endocrinologists, intensivists, or hospitalists. It has been demonstrated that Patient will be admitted to hospital for at least 24 h of observation and appropriate serial cardiac biomarkers assays involvement of appropriately trained specialists or specialty teams may reduce length of stay, improve glycemic control, and improve outcomes [9] . This multispecialty approach can be effective only if all members of the medical team have access to a patient's day-to-day treatment notes, laboratory data, and nursing updates. See Table 2 for examples of common barriers to improving and maintaining optimal blood glucose control in hospitalized patients [10] . Electronic medical records (EMRs) can certainly facilitate these goals, and communications protocols are essential. As hospitals begin to comply with ''meaningful use'' regulations for electronic health records as required under the Health Information Technology Act (HIT), all components of a structured insulin order sets should be incorporated into electronic insulin order sets [11] . A team approach is needed to establish hospital pathways. To achieve glycemic targets associated with improved hospital outcomes, hospitals will need multidisciplinary support to develop insulin management protocols that effectively and safely enable achievement of glycemic targets.
Results of a recent study suggest that systematic attention to hyperglycemia in the emergency department can result in better glycemic control during hospitalization for those patients who are subsequently admitted. The authors of the study conclude that, ''Standardization of insulin protocols in the ED and hospital settings leads to improvement in overall glycemic control with greater safety and efficacy than usual care'' [12] .
Approach to Blood Sugar Management in Patients with Critical and Noncritical Illness
Hyperglycemia is defined as blood glucose [ 140 mg/dL. An HbA1c value C 6.5 % is diagnostic of diabetes and serves to differentiate preexisting diabetes from stressinduced hyperglycemia. HbA1c is also useful in planning continuity of care, because in patients with diabetes, it provides information about pre-hospital glycemic control and helps to inform discharge planning [8] .
A helpful step in considering how to manage hyperglycemia in a hospitalized patient with a noncritical illness is to review the ADA's 2013 standards of care. All patients with diabetes who are admitted to the hospital should have their diabetes clearly documented in the medical record. The next step is to order blood glucose monitoring and to make results available to all members of a patient's health care team [1 • ].
Blood Glucose Goals Vary According to Whether a Patient is Critically or Noncritically Ill
In critically ill patients, insulin therapy should be initiated for treatment of persistent hyperglycemia starting at C 180 mg/dL (10 mmol/L). After insulin therapy has been started, the standard of care recommends a random glucose range of 140-180 mg/dL (7.8-10 mmol/L) for the majority of hospitalized patients. More stringent goals in the range of 110-140 mg/dL (6.1-7.8 mmol/L) may be appropriate for some patients, but only if this can be achieved without significant hypoglycemia. Finally, critically ill patients require an intravenous insulin protocol that has demonstrated efficacy and safety in achieving the desired glucose range without increasing risk for severe hypoglycemia [1 • ]. These goals make a case for the use of basal insulin in hospitalized patients. See Table 3 for examples of blood glucose goals for hospitalized patients.
In noncritically ill inpatients, no clear evidence that supports specific blood glucose goals has come to light, and there are no prospective RCT data to inform glycemic targets in this group of patients. Thus, recommendations must be based on clinical experience and judgment. However, for patients who receive insulin, premeal blood Table 2 Common barriers to improving and maintaining optimal blood glucose control in hospitalized patients [10] The standards of care also state that for noncritically ill patients, scheduled subcutaneous insulin with basal, nutritional (otherwise known as meal time or prandial), and correction components is preferred for achieving and maintaining glucose control. Moreover, glucose monitoring should be standard operating procedure in all nondiabetic patients who receive treatment that carries high risk for hyperglycemia, including high-dose glucocorticoid therapy, enteral or parenteral nutrition, or medications such as octreotide or immunosuppressive agents. If persistent hyperglycemia (C 180 mg/dl) is documented, patients can be treated to glycemic goals that match those for patients with diabetes, and an individualized plan for preventing and treating hypoglycemia should be developed. Episodes of hypoglycemia in the hospital should be documented in the medical record and tracked. For patients with diabetes for whom HbA1c testing results within the past 2-3 months are not available, guidelines recommend that clinicians consider obtaining an HbA1C on hospital admission. In addition, hospital physicians should also consider obtaining an HbA1C in patients with risk factors for undiagnosed diabetes who exhibit hyperglycemia while hospitalized [ 
The ADA recommendations for noncritically ill inpatients conclude with, ''Patients with hyperglycemia in the hospital who do not have a prior diagnosis of diabetes should have appropriate plans for follow-up testing and care documented at discharge'' [1 • ].
If we extend these recommendations to patients who present to the ED, then the ADA standard of care strongly supports the use of basal insulin in critically and noncritically ill patients in a hospital setting.
Patient Management: The Case for Basal Insulin
The traditional model of care among hospital-based physicians has been to treat the diabetic patient with a regular insulin on a sliding scale. It is simple, quick to order, and there is little perceived risk of a patient suffering an episode of hypoglycemia. However, current evidence suggests that while this approach is straightforward, it may not be the best for patient care. A state of persistent hyperglycemia leads to worsened outcomes and an increase of cost of care. A more global management approach to DM is needed. This approach begins and ends with basal and mealtime insulin.
Transitioning Care to the In-Patient Hospital
Optimal transition of care from the ED to inpatient status requires coordination among ED physicians and hospitalists to ensure continuity of care. The patient's course of care in the ED should be reviewed with the inpatient team. If possible, the rationale for use of specific antihyperglycemic agents, including insulin, should be shared with the receiving team to ensure smooth transition from ED to hospital service. It is critical that the process begin while the patient is in the ED, as hyperglycemia left untreated while in the ED has a profound impact on the ability of the inpatient team to attain euglycemia.
Basal Insulin Versus Sliding Scale Insulin
Basal insulin must be differentiated from traditional sliding scale insulin. According to the ADA standards of care, insulin therapy is the preferred method of glycemic control in majority of in-hospital clinical situations. Intravenous infusion is the preferred route of administration in the intensive care unit (ICU). In other hospital settings (including the ED), the standards recommend scheduled subcutaneous insulin that delivers basal, nutritional, and correction (supplemental) components. Typical dosing schemes are based on body weight, with some evidence that patients with renal insufficiency should be treated with lower doses [1 • ].
Basal Insulin
Patients who present to the ED or are hospitalized often require an insulin regimen that can change rapidly as their condition changes. A basal/bolus insulin regimen fulfills those criteria and mimics a normal insulin profile [8] . See Fig. 1 for examples of physiologic principles of the basal/ bolus insulin regimen. In contrast to a sliding-scale or correction scale insulin regimen, scheduled basal/bolus insulin can prevent hyperglycemia, while sliding or correction scale insulin regimens only lower hyperglycemia after it has occurred. Table 4 shows insulin types, brand names, onset, peak, and duration of action. A comparison of scheduled basal/bolus insulin with sliding scale insulin alone revealed that a significantly higher percentage of patients achieved goal glucose levels in the basal/bolus group compared with those in the sliding scale group (66 vs. 38 %) without an increase in hypoglycemia [13] .
Components of a Basal/Bolus Regimen
The three components of a basal/bolus regimen are basal insulin, meal or nutritional bolus insulin, and correction insulin (Fig. 1) . The ideal basal insulin provides a constant 24-h ''peakless,'' or tonic insulin level to suppress hepatic glucose release during the fasting state and between meals. Glargine and detemir deliver relatively peakless basal insulin. Glargine is preferred because it has a longer duration of action and permits true once-daily administration. When used appropriately, basal insulin should not cause hypoglycemia in patients who are restricted from oral nutritional intake (NPO).
The purpose of mealtime bolus insulin is to prevent predictable postprandial rise in glucose. Thus, bolus insulin can be given at each meal with one of the rapid-acting analogs (lispro, aspart, or glulisine). These insulin analogs offer rapid onset of action and typically reach peak levels within 60 min. Rapid-acting insulin analogs should be administered within 15 min before a meal, but regular insulin, due to its slower onset of action, must be given at least 30 min before a meal.
The purpose of correction insulin is to lower hyperglycemic glucose levels, rather than to cover nutritional hyperglycemia. However, in common with mealtime bolus insulin, rapid-acting analog formulations are a good choice for correctional insulin for patients who can eat [8] .
Sliding Scale Insulin
Prolonged therapy with sliding-scale insulin (SSI) as the sole regimen is ineffective in the majority of patients, increases risk of both hypoglycemia and hyperglycemia, and has recently been shown in a randomized trial to be associated with adverse outcomes in general surgery patients with type 2 diabetes [13] . Note that SSI is potentially dangerous in type 1 diabetes [9] .
In an inpatient setting, an insulin protocol based on standing orders in which one size does not fit all is typically used. Patients may receive a sliding scale regimen even if their pre-hospital HbA1c was within satisfactory limits. In actual use, the sliding scale typically depends on blood glucose levels that are tested every 6 h at bedside. In this setting, hospitalized patients may not be treated with basal insulin, and, given rapid-acting insulin acts for only 3-4 h, glucose test results reflect the intake of short-acting (regular) insulin alone, which lasts about 6-8 h, depending on dose. Another disadvantage of a sliding scale regimen is that it tends to have a cutoff point below which no insulin is administered. However, omitting a dose because a patient's glucose level has declined below the cutoff point can mean that no insulin is available for many hours and a consequent spike in blood sugar [14] .
NPH Insulin
NPH insulin should be avoided in hospitalized patients because it is characterized by a pronounced and variable 
Role of Oral and Noninsulin Parenteral Medications
Under most circumstances, patients should discontinue use of oral agents during acute illness unless hospitalization is to be very brief [8] .
• Metformin must NOT be used in patients who may require use of iodinated contrast studies (CT) or who have renal insufficiency.
• Use of sulfonylureas and metaglinides is associated with unpredictable hypoglycemia in patients who are not eating reliably.
• Use of thiazolidinediones can result in fluid retention, especially if used in combination with insulin.
• Use of parenteral glucagon-like peptide-1 and amylin agonists is associated with nausea, so these agents should be withheld in acutely ill patients.
The drawbacks to oral agents suggest that inpatient hyperglycemia may be best managed with insulin only. Patients can resume taking oral agents as they approach discharge or transfer to a non-acute setting [8] .
Determining Insulin Strategies
Total daily dose (TDD) of insulin can vary according to whether a patient is currently using insulin or is insulin naïve. For patients who are insulin naïve, a TDD of 0.3-0.6 U/kg of body weight is considered safe. As shown in Table 5 , leaner patients and those with renal insufficiency may be started on the lower dose (0.3-0.4 U/kg), and those who are obsess or are taking glucocorticoids can begin with the higher dose. Under certain circumstances, patients may require more or less insulin than their body weight would imply. Such circumstances include chronic obstructive pulmonary disease (COPD), use of glucocorticoids, cancer, renal insufficiency, and other acute and chronic conditions.
Patients who use basal-bolus insulin therapy take four injections a day, combining basal insulin and prandial insulin before meals. Basal-bolus insulin therapy allows for dosage flexibility and is well suited for patients with varied food intake or irregular meal patterns. An added advantage to basal-bolus insulin therapy is that a healthcare provider can adjust insulin doses on the basis of monitored blood glucose levels at each meal [10] .
Clinical studies in patients with type 1 and type 2 diabetes have consistently demonstrated that in patients who are eating normally, optimal glycemic control can be achieved with subcutaneous insulin when about 50 % of the TDD is given as basal insulin and the other 50 % as bolus insulin [16] . Keep in mind, however, that mealtime bolus doses must be determined on the basis of how much patients are eating [8] .
Premeal prandial insulin doses used on an inpatient basis can be 5 U per meal or approximately 7 % of the basal insulin dose, or, even more simply, or 1 U per 15 g carbohydrate (i.e. 1 carbohydrate exchange) [10] .
If premeal glucose is elevated, supplemental doses of rapid-acting insulin, correction doses, can be added to the mealtime dose. If premeal glucose is low, the dose can be decreased. Hospital staff adjust basal and prandial insulins independently to achieve target A1C levels and blood glucose levels [10] .
The classic way to think about the basal/bolus insulin dose calculation is to envision a 100 kg patient who will take 50 % of his or her insulin as basal insulin and the other 50 % as bolus. The formula is 100 kg 9 0.5 = 50 U total daily dose (TDD). One half of the TDD is long-acting basal insulin or 25 U, and 25/3 (for three meals a day) of prandial (aka mealtime or bolus) insulin at each meal.
Another calculation for an 80 kg patient is shown in Table 6 .
Intravenously administered insulin (insulin drip) is the treatment of choice for critically ill (ICU) patients who require insulin. When it is appropriate to transfer from IV insulin to subcutaneously administered insulin as a result of clinical improvement, the transition should not lead to deterioration in glycemic control. However, deterioration in control can occur when SSI is substituted for insulin infusions, or when doses of basal or nutritional insulin (or both) are underestimated or overestimated. It is essential to accurately estimate the initial adjustment to maintain 4 . Eighty percent of this amount would result in a potentially appropriate TDD [17, 18] . Table 7 shows a four-step sample conversion from IV to basal/bolus insulin, appropriate for patients who have required IV insulin while in an intensive care unit (ICU) and can transition to subcutaneous administration in preparation for transitioning to a medical service.
Premixed Insulin
Premixed insulins are available as 70 % NPH/30 % regular, 70 % insulin aspart protamine/30 % insulin aspart, 75 % insulin lispro protamine/25 % insulin lispro, or 50 % insulin lispro protamine/50 % insulin lispro, as shown in Table 4 . These mixtures contain postprandial (shorter-acting) and intermediate-release glucose control. These formulations can be administered at the largest meal once daily or at the two largest meals twice daily. Dosage adjustments are based on the pre-dinner glucose level if administered pre-breakfast, and on the fasting blood glucose level if administered pre-dinner [10] .
Premixed insulins are somewhat limited in their ability to reach glycemic targets unless given more frequently or in higher doses, which increases the potential for hypoglycemia and weight gain. The American Association of Clinical Endocrinologists (AACE) in its 2011 comprehensive care plan notes that premixed may be appropriate for patients who have difficulty adhering to a drug regimen. However, such preparations lack component dosage flexibility and can increase risk for hypoglycemia compared with basal insulin or basal-bolus regimens, which are more flexible [10] .
Diabetic patients are associated with longer hospital stay and greater perioperative morbidity and mortality, and are also associated with higher health care costs than in the nondiabetic population. Reasons for increased morbidity and mortality are partly the result of higher incidence of comorbid conditions such as coronary heart disease, hypertension, renal insufficiency and adverse effects of hyperglycemia on clinical outcomes [13] . These facts notwithstanding, hyperglycemia is often overlooked, and if identified, may be inadequately addressed due to fear of hypoglycemia.
Umpierrez and coworkers evaluated the use of basalbolus insulin with glargine once daily plus glulisine before meals as a means of managing blood glucose levels in general surgery patients with T2DM. A total of 211 patients were enrolled, 107 in the SSI (regular insulin sliding scale) group and 104 in the basal/bolus insulin group. Table 8 shows clinical characteristics, type of surgery, and blood glucose values during treatment.
Difference between groups in the frequency of the composite outcome, including wound infection, pneumonia, bacteremia, respiratory failure, and acute renal failure, were higher in the SSI group (24.3 %) than in basal-bolus group (8.6 %; P = 0.003) ( Table 9 ). There were reductions with basal-bolus as compared with SSI in wound infection (2.9 vs. 10.3 %; P = 0.05), pneumonia (0 vs. 2.8 %; P = 0.247), and acute renal failure (3.8 vs. 10.3 %; P = 0.106). In addition, the basal-bolus regimen resulted in lower, but not significant, reduction in postsurgical ICU admissions.
The investigators concluded that the basal/bolus regimen was associated with better glycemic control and a lower rate of hospital complications than use of SSI, and that it did not increase the number of severe hypoglycemic events. Results of this study support the superiority of Table 6 Basal/bolus insulin dose calculation for an 80-kg patient with BMI of 28 kg/m 2 and normal renal function [8] Step 1 TDD calculation TDD = 0.5 U/kg body weight 9 80 = 40 U
Step 2 Basal insulin dose calculation Basal insulin dose = 50 % of TDD = 50 % of 40 U = 20 U glargine
Step 3 Bolus insulin dose calculation
Bolus insulin dose per meal = (50 % of TDD)/ 3 = (50 % of 40 U)/3 = 20/3 = 6.3 U, or *6 U of rapid-acting insulin before each meal. If the patient or nurse estimates that the patient is only eating 50 % of the food on the tray, a reduced dose of 3 U should be ordered instead of the full dose of 6 U
Step 4 Correctional scale estimation Assessment of correctional scale insulin is based on TDD. For a patient with a TDD of 40 U, the low correctional scale should be ordered Table 7 Basal/bolus insulin dose calculation for a patient started on diet who required 2 U/h of insulin overnight while NPO [8] Step 1 Basal dose calculation Patient's hourly insulin infusion rate while NPO = 2 U/h 24-h basal insulin dose during stress = 249 hourly infusion rate = 24 9 2 = 48 U Adjusted basal dose accounting for stress reduction = 2/ 3 9 24-h basal rate = 2/3 9 48 = 32 U of glargine
Step 2 TDD calculation TDD = dose is 29 adjusted basal dose = 2 9 32 = 64 U
Step 3 Mealtime bolus dose calculation
Patient just started to eat, so 10 % of bolus dose can be started with each meal = 0.1 9 32 = 3 U
Step basal-bolus insulin regimens in general surgery patients with T2DM over the use of SSI alone.
Patient Transitions
Patients transitioning from hospital to community require appropriate education and follow-up if they are to maintain glycemic control and achieve glycemic goals. An organized multidisciplinary team may be best qualified deliver transitional and ongoing care for patients with DM. Members of such a team can include a primary care physician, endocrinologist, physician assistant, nurse practitioner, registered nurse, certified diabetes educator (CDE), dietitian, exercise specialist, and mental health care professional [10] . Patient education should be comprehensive, particularly for newly diagnosed patients, and should stress self-management strategies. At diagnosis and throughout their lives, and particularly during health crises, patients should receive information and counseling about therapeutic lifestyle management that includes medical nutrition therapy (with reduction and modification of caloric and fat intake to achieve weight loss in those who are overweight or obese), appropriate physical activity, avoidance of tobacco products, and adequate quantity and quality of sleep [10] .
Optimal post-discharge follow-up should occur over the long term with a primary care physician, an endocrinologist, a diabetes educator, and other health care professionals such as an ophthalmologist, a vascular specialist, a cardiologist, and a nephrologist, as appropriate.
The most critical time in all of in-patient management is the transition from one medical setting to the next. The time for medical errors and miscommunication heightens during these transition points. Providers of hospital care should be very cautious in their approach with patients on insulin or other diabetic agents. Often times, patients are unable to completely comprehend their treatment or follow-up plans post-discharge. It is imperative that we relate all information to the next care provider scheduled to care for the patient, i.e. the primary care provider (PCP) or endocrinologist. Transition of care management, as it relates to insulin and diabetic agents, carries more importance than for other typical medications, given the risk of complications from these medications. Communication with a patient's family or caregiver is also extremely useful in situations that involve insulin. Finally, follow-up education and re-education will help the patient understand their disease process and transition back to a healthy lifestyle.
Summary
Given the current prevalence of DM, how best to address hyperglycemia in the ED is an increasingly relevant issue in which the principal goals are to minimize disruption of the metabolic state and achieve a stable glycemic balance as promptly as possible. Transition of care from the ED to an inpatient service can result in gaps in comprehensive care, particularly in patients with DM who may have other serious comorbidities. Even in patients without a previous diagnosis of DM, uncontrolled hyperglycemia, regardless of cause during hospitalization, is associated with adverse outcomes and longer lengths of stay. In contrast to a sliding scale or correction scale insulin regimen, scheduled basal/bolus insulin can prevent hyperglycemia, while sliding or correction scale insulin regimens only lower hyperglycemia after it has occurred. The three components of a basal/bolus regimen are basal insulin, meal or nutritional bolus insulin, and correction insulin. The ideal basal insulin provides a constant 24-h tonic insulin level to suppress hepatic glucose release during the fasting state and between meals. The purpose of mealtime bolus insulin is to prevent predictable postprandial rise in glucose. Thus, bolus insulin can be given at each meal with one of the rapid-acting analogs.
Intravenously administered insulin (insulin drip) is the treatment of choice for critically ill patients who require insulin. When it is appropriate to transfer from IV insulin to subcutaneously administered insulin as a result of clinical improvement, the transition should not lead to deterioration in glycemic control. Patients transitioning from hospital to community require appropriate education and follow-up if they are to maintain glycemic control and achieve glycemic goals. Patient education should be comprehensive, particularly for newly diagnosed patients, and should stress self-management strategies.
The most critical time in all of in-patient management is the transition from one medical setting to the next. Transition of care management, as it relates to insulin and diabetic agents, carries more importance than for other typical medications, given the risk of complications from these medications. The ideal management plan for patients with diabetes involves coordination, knowledge-sharing and constant vigilance to ensure that patients remain euglycemic through the entire process as they move from the ED to the hospital and back home again.
